Yes, stock's been getting beat up technically, but here's what's on the docket for 2013:
-- European approval of Erivedge (CHMP committee meeting Feb or Mar?)
-- Phase I results of CUDC-907
-- Presentation on the new IAP drug at ASCO mid-year
-- Look in on Operable BCC use for Erivedge (huge market!)
We may look back on this sub-$3 level as a huge buying opp by 4Q ....
The potential market for op bcc is actually astronomical if you think about it, although you have to wonder what percentage of that potential will actually be realized. I imagine that some of the MDs who have been prescribing erivedge for the 2% of patients who have non op bcc will be apt to prescribe it for those who have op bcc, although some may already be doing so off-label to begin with. Regardless the potential is enormous, moreso than simply the addition of Europe (hopefully later this week), though that would add anywhere from 33 to 50 percent to sales itself. Don't forget the pancreatic cancer studies either! That may be a bit more of a dark horse, but it is another potentially enormous market, to say the least. Dr. Fattaey can only help their efforts to reach these milestone achievements.